Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)

Davidson, EJ; Faulkner, RL; Sehr, P; Pawlita, M; Smyth, LJC; Burt, DJ; Tomlinson, AE; Hickling, J; Kitchener, HC; Stern, PL

Abstract

Heterologous prime-boost vaccination schedules employing TA-HPV, a vaccinia virus encoding HPV 16/18 E6 and E7, in combination with TA-CIN, an HPV 16 L2E6E7 fusion protein, may offer advantages over the use of either agent alone for the immunotherapy of human papillomavirus (HPV) type 16-associated vulval intraepithelial neoplasia (VIN). In the present study, 10 women with HPV 16-positive high grade VIN, previously primed with TA-HPV, received three booster immunisations with TA-CIN. All but one demonstrated HPV 16-specific proliferative T-cell and/or serological responses following vaccination. Three patients additionally showed lesion shrinkage or symptom relief, but no direct correlation between clinical and immunological responses was seen.

Citation

Davidson, E., Faulkner, R., Sehr, P., Pawlita, M., Smyth, L., Burt, D., …Stern, P. (2004). Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine, 22(21-22), 2722-2729. https://doi.org/10.1016/j.vaccine.2004.01.049

• Journal Article Type: Article
• Publication Date: Jan 1, 2004
• Deposit Date: Dec 23, 2010
• Journal: Vaccine
• Print ISSN: 0264-410X
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 22
• Issue: 21-22
• Pages: 2722-2729
• DOI: https://doi.org/10.1016/j.vaccine.2004.01.049
• Publisher URL: http://dx.doi.org/10.1016/j.vaccine.2004.01.049